Outrun Therapeutics CEO Carolyn Porter is in Cambridge today for the BioIndustry Association (BIA)'s annual Women in Biotech event! ? To celebrate the upcoming International Women's Day (#IWD2025), the event brings together female leaders from across the sector for an important day filled with exciting and thought-provoking discussions, panels, and keynote speakers. ? #WomenInBiotech
关于我们
Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.
- 网站
-
https://outruntx.com/
Outrun Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 类型
- 私人持股
Outrun Therapeutics员工
动态
-
BiotechTV visited Carolyn Porter and the Outrun Therapeutics team yesterday to discuss our goal of creating a new category of therapeutics by stabilising proteins via drugging E3 ligases #outruntherapeutics #biotech #womeninscience #biotechtv #proteinstabilisation #e3ligase #drugdiscovery
???????? ???? ????????????????: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases. CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit. The first goal is to go after hard to treat solid tumors. Full video: https://lnkd.in/g5dN6J4R BiotechTV's tour of Scotland's life sciences industry is brought to you by The Scottish National Investment Bank. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills
-
Ahead of #IWD2025, Outrun Therapeutics CEO Carolyn Porter took part in the below Q&A, sharing her thoughts on this important initiative and reflecting on her career and experiences as a female leader in the life sciences industry. ?? IWD honours the achievements of women across all aspects of life and at Outrun we continue to celebrate our incredible female colleagues who are driving the development of our proprietary discovery platform which can identify first-in-class small molecule drugs targeting E3 ligases. ?? You can learn more about this important initiative via the link in the comments. #IWD2025 #AccelerateAction #E3ligases
-
Outrun Therapeutics CEO Carolyn Porter is in Cambridge today for the BioIndustry Association (BIA)'s annual Women in Biotech event! ? To celebrate the upcoming International Women's Day (#IWD2025), the event brings together female leaders from across the sector for an important day filled with exciting and thought-provoking discussions, panels, and keynote speakers. ? #WomenInBiotech
-
-
The Outrun Therapeutics team, and CEO Carolyn Porter are proud to celebrate #womenandgirlsinscience this week ???????????????????????????? #womeninscience2025 #womeninstem #WomenInScience #outruntherapeutics #stem #science #biotech #drugdiscovery #e3ligase #proteinstabilisation
-
-
The Outrun Therapeutics team, and CEO Carolyn Porter are proud to celebrate #womenandgirlsinscience this week ???????????????????????????? #womeninscience2025 #womeninstem #WomenInScience #outruntherapeutics #stem #science #biotech #drugdiscovery #e3ligase #proteinstabilisation
-
-
Outrun Therapeutics CEO Carolyn Porter recently spoke with Roohi Mariam Peter of Labiotech.eu ahead of its #WorldCancerDay feature on the 'Trends in cancer therapeutics to look forward to in 2025'. ? Carolyn emphasised the importance of finding ways to treat cancers for which there are still few or no available treatment options for patients, while highlighting Outrun's novel approach as one of the ways in which the sector is looking to overcome the growing resistance to targeted therapies. ? You can read the thoughts of Carolyn and her fellow industry leaders in full via the following link: https://lnkd.in/emUiQTHt ? #oncology #drugdiscovery #biotech
-
Today marks #WorldCancerDay, and at Outrun Therapeutics we are proud to support this year's theme #UnitedbyUnique, which places people at the heart of care and focuses on exploring new ways of making a difference. ? Cancer is a devastating disease, but it is more than just a medical diagnosis, with each case involving a uniquely human story. ? You can learn more about this important initiative on the World Cancer Day website: https://lnkd.in/drnuZeE ? At #Outrun, we are working to advance our proprietary X-E?L discovery platform to identify first-in-class small molecule drugs targeting E3 ligases to address hard-to-treat solid tumours. ? Visit our website to discover more about the relevance of E3 ligase inhibition as a therapeutic approach to treat cancer, and how we are leading the way. ? #oncology #biotech #drugdiscovery
-
-
We are so lucky to have such a diverse range of companies in the BioDundee Community such as Outrun Therapeutics a spin out from Prof. Satpal Virdee’s lab at the world-renowned MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee.?Outrun Therapeutics is a biotech company focused on developing small molecule inhibitors of E3 Ligases to stabilize proteins to treat cancer.?To find out more about the company you can view their profile.
-
Outrun Therapeutics CEO Carolyn Porter and CSO Matthew Fyfe had a wonderful evening at the BioIndustry Association (BIA) annual Gala Dinner at the Roundhouse in London last night! ? They joined fellow industry leaders in the UK #biotech field for an evening of celebration ahead of what promises to be a pivotal year for Outrun and the wider biotech ecosystem. ? #outruntherapeutics #BIA #bioindustryassociation
-